NASDAQ · TARS
Healthcare · Biotechnology
$72.64
Down-$0.68 (-0.93%)
Updated Nov 4, 2026, 6:06 AM
SID Score
4.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance · TARS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
TARS closed at $72.64 after 21 trading sessions, down 1.98% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $74.30 | $75.36 | $70.39 | $72.64 | 756.97K |
| Nov 2, 2026 | $74.88 | $76.09 | $72.395 | $73.32 | 428.69K |
| Oct 30, 2026 | $74.99 | $76.27 | $74.2979 | $74.85 | 595.21K |
| Oct 29, 2026 | $72.90 | $74.76 | $72.7363 | $74.20 | 458.42K |
| Oct 28, 2026 | $69.61 | $72.44 | $69.50 | $72.05 | 400.07K |
| Oct 27, 2026 | $69.78 | $71.71 | $69.14 | $70.76 | 747.96K |
| Oct 26, 2026 | $68.37 | $71.62 | $68.355 | $70.03 | 877.13K |
| Oct 23, 2026 | $71.48 | $71.705 | $67.65 | $68.20 | 556.62K |
| Oct 22, 2026 | $70.93 | $73.11 | $69.55 | $72.08 | 688.66K |
| Oct 21, 2026 | $70.85 | $72.81 | $70.20 | $70.50 | 945.91K |
| Oct 20, 2026 | $69.54 | $72.46 | $67.93 | $71.03 | 898.98K |
| Oct 19, 2026 | $68.08 | $70.94 | $68.08 | $69.50 | 682.55K |
| Oct 16, 2026 | $70.87 | $70.87 | $67.95 | $68.07 | 2.87M |
| Oct 15, 2026 | $72.585 | $74.94 | $70.55 | $70.99 | 1.4M |
| Oct 14, 2026 | $70.57 | $73.35 | $70.03 | $72.29 | 1.17M |
| Oct 13, 2026 | $74.50 | $75.02 | $70.32 | $70.82 | 1.63M |
| Oct 12, 2026 | $73.20 | $76.64 | $72.975 | $74.40 | 1.46M |
| Oct 9, 2026 | $72.22 | $73.93 | $71.20 | $73.16 | 481.75K |
| Oct 8, 2026 | $73.07 | $74.515 | $70.80 | $72.22 | 642.11K |
| Oct 7, 2026 | $73.58 | $74.675 | $73.30 | $73.61 | 542.28K |
| Oct 6, 2026 | $74.48 | $75.255 | $72.94 | $74.11 | 432.43K |
The latest Smart Investors Daily articles mentioning TARS.
Company
Market Activity
Research & News
TARS research
Company profile and research snapshot.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 24, 2026 | Goldman Sachs | Buy | — |
| Sep 16, 2026 | Barclays | Overweight | — |
| Sep 8, 2026 | Jefferies | Buy | — |
| Aug 12, 2026 | Oppenheimer | Outperform | — |
| Jul 31, 2026 | Mizuho | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 2, 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 30.8% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SeekingAlpha · Nov 1, 2026
Tarsus Pharmaceuticals may be undervalued after its pullback, with Xdemvy growth, pipeline upside, and key catalysts ahead. Read the full analysis here on TARS stock.
Yahoo · Oct 29, 2026
Gilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 29, 2026
IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tar
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TARS.
